The Australian market has faced a challenging week, with ASX 200 futures indicating a slight decline as global trade tensions impact investor sentiment. Despite the broader market's volatility, penny stocks continue to capture interest for their potential to offer growth opportunities in smaller or newer companies. Though considered niche, these stocks can still hold value when backed by strong financial health, and we explore three such examples that may combine balance sheet strength with long-term potential.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.61 A$75.95M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.10 A$147.1M ★★★★★★ Regal Partners (ASX:RPL) A$2.78 A$932.4M ★★★★★★ GTN (ASX:GTN) A$0.595 A$116.84M ★★★★★★ IVE Group (ASX:IGL) A$2.26 A$350.05M ★★★★★☆ CTI Logistics (ASX:CLX) A$1.62 A$126.38M ★★★★☆☆ West African Resources (ASX:WAF) A$2.21 A$2.52B ★★★★★★ MotorCycle Holdings (ASX:MTO) A$1.855 A$136.91M ★★★★★★ NRW Holdings (ASX:NWH) A$2.73 A$1.25B ★★★★★☆ Accent Group (ASX:AX1) A$1.76 A$996.16M ★★★★☆☆

Click here to see the full list of 983 stocks from our ASX Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Aussie Broadband

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aussie Broadband Limited offers telecommunications and technology services in Australia, with a market cap of A$1.13 billion.

Operations: The company's revenue is derived from several segments, including Residential (A$628.51 million), Wholesale (A$143.55 million), Business (A$102.99 million), and Enterprise and Government (A$93.51 million).

Market Cap: A$1.13B

Aussie Broadband Limited, with a market cap of A$1.13 billion, is experiencing substantial growth in its telecommunications and technology services across various segments. The company reported sales of A$588.49 million for the half year ended December 31, 2024, indicating robust revenue growth compared to the previous year. Despite a large one-off loss impacting recent financial results, Aussie Broadband's debt levels are manageable with satisfactory net debt to equity and well-covered interest payments by EBIT. However, short-term assets do not fully cover long-term liabilities. Notably, leadership changes are underway as co-founder Phillip Britt transitions to a non-executive role while maintaining involvement as a Special Technical Adviser amidst ongoing strategic projects like the fibre optic network expansion.

Jump into the full analysis health report here for a deeper understanding of Aussie Broadband. Review our growth performance report to gain insights into Aussie Broadband's future.

Story Continues

ASX:ABB Revenue & Expenses Breakdown as at Mar 2025

IGO

Simply Wall St Financial Health Rating: ★★★★★★

Overview: IGO Limited is an Australian exploration and mining company that focuses on discovering, developing, and operating assets related to metals for clean energy, with a market cap of A$3.02 billion.

Operations: The company generates revenue primarily from its Nova Operation, which accounts for A$460.8 million, and the Forrestania Operation, contributing A$153 million.

Market Cap: A$3.02B

IGO Limited, with a market cap of A$3.02 billion, faces challenges as it remains unprofitable with increasing losses over the past five years. Despite being debt-free and having short-term assets exceeding both short and long-term liabilities, the company reported a significant net loss of A$782.1 million for the half-year ended December 31, 2024. Revenue from its Nova and Forrestania Operations totaled A$613.8 million but declined compared to the previous year. Recent management changes include Cameron Wilson's appointment as Company Secretary amid strategic shifts following non-payment of an interim dividend due to liquidity constraints and cash outflows.

Click to explore a detailed breakdown of our findings in IGO's financial health report. Examine IGO's earnings growth report to understand how analysts expect it to perform.ASX:IGO Debt to Equity History and Analysis as at Mar 2025

Race Oncology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Race Oncology Limited is a clinical stage biopharmaceutical company dedicated to developing treatments for cancer patients with unmet needs, with a market cap of A$217.15 million.

Operations: Race Oncology generates its revenue primarily from operations in Australia, amounting to A$5.25 million.

Market Cap: A$217.15M

Race Oncology, with a market cap of A$217.15 million, is pre-revenue and currently unprofitable, though it reported a small net income of A$0.50 million for the half-year ended December 31, 2024. The company remains debt-free and has short-term assets of A$19 million exceeding its liabilities. Revenue is forecast to grow by 34.62% annually despite projected earnings declines over the next three years. Recent board changes include Dr Megan Baldwin's appointment as an Independent Non-Executive Director, bringing extensive oncology drug development experience and strategic insight from her tenure at Opthea Limited and Genentech (Roche).

Unlock comprehensive insights into our analysis of Race Oncology stock in this financial health report. Gain insights into Race Oncology's outlook and expected performance with our report on the company's earnings estimates.ASX:RAC Revenue & Expenses Breakdown as at Mar 2025

Summing It All Up

Explore the 983 names from our  ASX Penny Stocks screener here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:ABB ASX:IGO and ASX:RAC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments